Pharmaceutical Intermediate Doxofylline Raw Powder CAS 69975-86-6 Doxofylline

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: 98%
• Model NO.: HRK-Doxofylline
• Product Name: Doxofylline
• Certificate: GMP ISO USP Bp
• Assay: 98% Min
• Test: HPLC
• Mf: C11h14n4o4
• MW: 266.25
• Active Ingredient: Doxofylline
• Sample: Doxofylline Avaliable
• Grade Standard: Medicine Grade
• Application: Apis Raw Materials
• Type of Product: Auxiliaries and Other Medicinal Chemicals
• Storage: Cool Dry Place
• Shelf Life: 2 Years Proper Storage
• Color: White
• Place of Origin: Shaanxi, China
• Transport Package: 1kg Per Foil Bag, 10 Bags Per Carton. 25 Kg Per Dr
• Specification: 2% min
• Trademark: Henrikang
• Origin: Shaanxi China
• Production Capacity: 500000kg/Year

Product Description

   Pharmaceutical Intermediate Doxofylline Raw Powder CAS 69975-86-6 Doxofylline

Product name	Pharmaceutical Intermediate Doxofylline Raw Powder CAS 69975-86-6 Doxofylline
Appearance	White powder
MF	C11H14N4O4
Assay	99%
Shelf Life	24 months when properly stored
Storage	Keep in a cool, dry, dark location

What is Doxofylline Powder ? Doxofylline, also known as dosofitline, is an oxycycloamyl methyl derivative of theophylline. It has a significant inhibitory effect on phosphodiesterase, and can directly act on bronchus and relax smooth muscle. Its effect is stronger than aminophylline, and has antitussis effect for a long time without dependence. No central, gastrointestinal and other adverse reactions, does not affect cardiac function. For bronchial asthma and other lung diseases with bronchospasm.

Application of Doxofylline Powder

Wholesale Doxofylline acts as a PDE inhibitor and increases cAMP levels, so it can be used to treat asthma
and COPD. The EC50 value of Doxofylline was 15 times higher than that of aminophylline in inhibiting adenosine
induced relaxation of tracheal smooth muscle, and the EC50 value of Doxofylline was 15 times higher than that
of aminophylline in reducing adenosine's effect on negative atrial muscle force in guinea pigs. Doxofylline can
effectively reduce the opening probability of calcium-activated potassium channels due to the shortened opening
cycle and prolonged closing time. Compared with theophylline, Doxofylline greatly reduces its affinity for adenosine
A1 and A2 receptors, which may give it a better safety profile. In addition, unlike theophylline,Doxofylline does not
interfere with calcium ion influx or antagonize the action of calcium channel blockers.

Our Certificate

Our Service